Management of Cerebral Metastases from Melanoma Treated at a Single Institution

Manejo de metástases cerebrais de melanoma tratadas em uma única instituição

Michael Ricardo Lang1  Luis Renato Garcez de Oliveira Mello2  Vitor Hugo Boer3  
Celso Itiberê Bernardes4  Leandro José Haas4  Danielle De Lara4  Lucas Eduardo Bonadio1  
Felipe Laurindo Cabral1  Gabriel Hoher Peres1  Edson Machado Shirai Missugiro5  
Renann Vicenzoto de Castro e Souza5

1 MR, Neurosurgery, Hospital Santa Isabel, Universidade Regional de Blumenau, Santa Catarina, Brazil  
2 Professor, Neurosurgery, Chief of Clinic Surgery, Head for Neurosurgery Residency, Hospital Santa Isabel, Universidade Regional de Blumenau, Santa Catarina, Brazil  
3 Professor, Neurosurgery, Chief of Neurologic Surgery, Hospital Santa Isabel, Universidade Regional de Blumenau, Santa Catarina, Brazil  
4 Neurosurgeon, Hospital Santa Isabel, Blumenau, Santa Catarina, Brazil  
5 MD, Academic, Universidade Regional de Blumenau, Blumenau, Santa Catarina, Brazil

Address for correspondence Michael Ricardo Lang, MD, Hospital Santa Isabel, Universidade Regional de Blumenau, SC, Brazil (e-mail: michael.r.lang@hotmail.com).

Abstract

Objective  This retrospective study aimed to analyze prognostic factors, effects of treatment, and survival outcome of patients with brain metastasis from melanoma at a single institution over the last 22 years.

Methods  Study transversal retrospective of 34 patients with brain metastases from melanoma, histologically proven, surgically treated by the Department of Neurosurgery at the Hospital Santa Isabel, Blumenau, over 22 years.

Results  The median patient age was 50 years and 67.6% of the patients were men. Most patients (70.6%) had a single cerebral metastasis and 29.4% had two three injuries. Twenty percent of the patients in this series had evidence of extracranial metastasis. The KPS at presentation was ≥70 in 12 patients (35.2%). Evidence of recurrent intracranial melanoma was found during follow-up review in 17.6% of patients. The overall median survival time from diagnosis of cerebral metastasis was 14.4 months. The absence of extracranial metastasis was associated with a significantly prolonged survival (p = 0.052), as was adjuvant therapy (p = 0.02).

Conclusion  The early diagnosis, with total resection of melanoma metastasis and association of adjuvant therapies showed a positive influence on survival. However, the number of lesions and extracranial disease decreased the survival rates.

Keywords  ► metastatic melanoma  
► brain metastases  
► neurosurgery


Management of Cerebral Metastasis from Melanoma

Introduction

Cutaneous melanoma is one of the most common tumors to metastasize (8%) to the brain; is currently the third most common cause of cerebral metastasis, after lung (17%), renal cell (10.5%), and breast (5.2%) cancers; and is the most common cancer in young adults in Australia and in many other Western countries, with an estimated lifetime risk of between 1:25 and 1:87.1–5 Large clinical series show that brain metastasis (BM) are diagnosed in 10 to 40% of melanoma patients during their lifetime, and autopsy data demonstrate that 49 to 73% of patients who die of disseminated metastatic melanoma have brain involvement.4,6,7 Improvements in imaging quality and accessibility have also contributed to the increased number of patients in whom metastasis is diagnosed.8

Melanoma has a propensity for multiorgan involvement, and central nervous system complications are frequent. Metastatic spread to the brain is the most serious event in the course of melanoma because it carries the worst prognosis of all visceral metastasis and represents the major cause of death in patients with disseminated disease.6 The prognosis of patients with disseminated melanoma is particularly poor if cerebral metastasis is present.5,8

The recent management of cerebral melanoma metastasis mainly depends on the number and size of the metastases and on extracranial extension of the disease. Neurosurgery or stereotactic radiosurgery (STR) is usually offered to patients with single or few metastatic lesions. However, surgical removal is a mainstay. Patients who are not eligible for surgery or STR are usually offered whole-brain radiotherapy (WBRT), although no survival advantage has been demonstrated to date.1,2,6 Nevertheless, surgical resection in conjunction with WBRT is feasible in a subgroup of these patients and may prolong their survival.5,8 Generally accepted standards for the application of different treatment modalities in patients with BM from melanoma do not exist so far. Oncologists had little to offer, given that chemotherapy generally does not penetrate the blood-brain barrier.9

This retrospective study aimed to analyze prognostic factors, effects of treatment, and survival outcome of patients with BM from melanoma at a single institution over the last 22 years.

Clinical Material and Methods

From January 1991 to April 2013, total 34 patients with histologically proven cerebral metastasis from melanoma underwent surgical treatment in the Department of Neurosurgery at the Santa Isabel Hospital. Most patients lived in Blumenau, with small numbers living in other cities around.

Clinical data on these patients were collected retrospectively from their medical records, including operative and pathologic reports, and information from the office files of their neurosurgeons. Detailed follow-up review was conducted by telephone contact with patients or their family members. The following information was obtained: demographic, time interval between diagnoses of primary melanoma and BM, localization and number of BM, Karnofsky performance status (KPS), presence of extracranial disease, administered treatment, response to treatment, date of death or last follow-up, and cause of death.

Diagnosis of BM from melanoma was based on computed tomography (CT) and magnetic resonance imaging (MRI)
scans. Usually, patients were offered surgery if they had one or few surgically accessible BM and good KPS. STR was not available in our department. Patients, who received WBRT, usually commencing within 6 weeks of surgery, were treated with a total dose of 30 Gy with different fractionations regimens. Systemic chemotherapy was administered at some time after craniotomy, mainly for progressive extracranial disease.

Follow-up images were obtained by the neurosurgeon by using CT and MRI scans were obtained in patients being considered for reoperation.

**Statistical Analysis**

Kaplan–Meier survival curves and median values were calculated by standard formulas with commercially available software (EPINFO, 2006 e EPIDATA). A comparison of the median survival times among treatment groups was performed using log-rank tests. Standard tests of multivariate and univariate analysis were performed using the test with Bartlett’s Test for Inequality of Population Variances and parametric test ANOVA, and test for two samples Mann–Whitney/Wilcoxon. Statistical significance was defined at the 5% level.

**Results**

The demographic profile of the patients included in the study is summarized in **Table 1**. The median patient age was 50 years (range, 23–68 years) and 67.6% of the patients were men. A history of melanoma was found in 16 patients (47%), with a median interval of 12.2 months from diagnosis of primary melanoma. The remaining 18 patients (53%) presented with a cerebral metastasis as the first evidence of melanoma.

**Table 1** Demographic features in 34 patients who underwent craniotomy for cerebral metastasis of melanoma

<table>
<thead>
<tr>
<th>Variable</th>
<th>No of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age in years</strong></td>
<td></td>
</tr>
<tr>
<td>23–29</td>
<td>8 (23.3)</td>
</tr>
<tr>
<td>30–49</td>
<td>8 (23.3)</td>
</tr>
<tr>
<td>50–68</td>
<td>18 (53.3)</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>23 (67.6)</td>
</tr>
<tr>
<td>F</td>
<td>11 (32.4)</td>
</tr>
<tr>
<td><strong>Time at initial diagnosis until cerebral metastases in months</strong></td>
<td></td>
</tr>
<tr>
<td>&lt;1†</td>
<td>18 (53)</td>
</tr>
<tr>
<td>1–6</td>
<td>6 (17.6)</td>
</tr>
<tr>
<td>7–12</td>
<td>3 (8.9)</td>
</tr>
<tr>
<td>13–24</td>
<td>3 (8.9)</td>
</tr>
<tr>
<td>&gt;24</td>
<td>4 (11.6)</td>
</tr>
</tbody>
</table>

†Melanoma was diagnosed following presentation with cerebral metastasis.

The clinical characteristics of all patients at the time their cerebral metastasis was diagnosed are presented in **Table 2**. Most patients (70.6%) had a single cerebral metastasis. This was assessed using CT scanning only over the period of 1991 through 1998 and by MRI beginning in 1998. Of the remainder, 14.7% had two metastases and the same number had three metastases; 91% of the patients had supratentorial lesions. The locations of single cerebral lesions were frontal (50%), parietal (5%), temporal (40%), and occipital (1%). Overall, more than 20% of the patients in this series had evidence of extracranial metastasis at the time their cerebral metastatic disease was diagnosed. The KPS at presentation was ≥70 in 12 patients (35.2%).

The treatment details for the cerebral metastases and patient outcome are given in **Table 3**. A macroscopically complete tumor excision was achieved in 38.3% of patients. Subtotal resection or biopsy sampling were performed in the remainder, based on an assessment by the surgeon at the time of the procedure. Most patients (64.7%) had either improved or unchanged neurologic status when assessed at the time of discharge from the hospital.

Clinical or radiologic evidence of recurrent intracranial melanoma was found during follow-up review in 17.6% of patients. Recurrence was assessed using CT scanning, followed by MRI if further surgical treatment was contemplated. Radiosurgery was not available for the patients in this series.

**Table 2** Characteristics of 34 patients with cerebral metastasis of melanoma

<table>
<thead>
<tr>
<th>Variable</th>
<th>No. of patients (%)</th>
<th>Median survival (mo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karnofsky at presentation</td>
<td></td>
<td>p = 0.0940</td>
</tr>
<tr>
<td>0–60</td>
<td>22 (64.7)</td>
<td>3</td>
</tr>
<tr>
<td>70–100</td>
<td>12 (35.3)</td>
<td>35.2</td>
</tr>
<tr>
<td><strong>No. of metastasis</strong></td>
<td></td>
<td>p = 0.487</td>
</tr>
<tr>
<td>1</td>
<td>24 (70.6)</td>
<td>21</td>
</tr>
<tr>
<td>2</td>
<td>5 (14.7)</td>
<td>3.4</td>
</tr>
<tr>
<td>≥3</td>
<td>5 (14.7)</td>
<td>3.4</td>
</tr>
<tr>
<td><strong>Location of metastasis</strong></td>
<td></td>
<td>p = 0.089</td>
</tr>
<tr>
<td>Supratentorial</td>
<td>31 (91)</td>
<td>14.3</td>
</tr>
<tr>
<td>Infratentorial</td>
<td>3 (9)</td>
<td>15</td>
</tr>
<tr>
<td><strong>Extracranial metastasis</strong></td>
<td></td>
<td>p = 0.0528</td>
</tr>
<tr>
<td>yes</td>
<td>7 (20.6)</td>
<td>1.42</td>
</tr>
<tr>
<td>no</td>
<td>27 (79.4)</td>
<td>17.57</td>
</tr>
<tr>
<td><strong>Extent of extracranial metastases</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin</td>
<td>27 (79.4)</td>
<td>17.57</td>
</tr>
<tr>
<td>Lung</td>
<td>2 (6)</td>
<td>3.5</td>
</tr>
<tr>
<td>Liver, lung</td>
<td>1 (2.6)</td>
<td>0</td>
</tr>
<tr>
<td>Liver</td>
<td>2 (6)</td>
<td>1</td>
</tr>
<tr>
<td>Paravertebral, spinal cord</td>
<td>2 (6)</td>
<td>1</td>
</tr>
</tbody>
</table>
Progressive intracerebral melanoma was the direct cause of death in 64.7% of the entire series. The remainder died of progressive extracranial disease.

The overall median survival time from diagnosis of cerebral metastasis was 14.4 months, which is demonstrated in Fig. 1. On univariate analysis, the absence of extracranial metastasis was associated with a significantly prolonged survival ($p = 0.052$), as was adjuvant therapy ($p = 0.02$). Other factors that did not affect survival included patient age, sex, the time interval from primary melanoma to cerebral metastasis, and the location of the cerebral lesion (infra- or supratentorial).

Although the median survival of patients with single lesions was higher (21 months), there was no statistical significance ($p = 0.48$) (Fig. 2).

### Discussion

Melanoma has the highest propensity to metastasize to the brain of all primary neoplasms in adults, and this paper shows that the most prevalent age range is between 50 and 75 years.
69 years (53.3%). This population is affected in their productive age, aggressive therapy contributes impressively in some cases. Patients with melanoma tend to be younger (~50 years old) and often have excellent KPS scores on admission; however, our study found that KPS less than 70 were most frequent (64.7%) and the patients was oldest (50–69 years old).

In this series, there was early diagnosis of BM, on average 12.2 months after diagnosis of the primary disease, which typically occurs late in the course of melanoma, with an interval from 2.2 to 3.8 years. In the study of Wronske et al, the median time from diagnosis of the primary tumor to that of the BM was 14.4 months.\(^4,6,11–13\)

In addition, Sampson et al investigated that patients with a single lesion and an absence of extracranial metastasis who initially presented with BM have a better prognosis. This article was evidenced that the most significant determinant of survival is the absence of extracranial disease (17.34 menses), unlike those who had extracranial disease (1.42). The same was asserted by Nieder et al that patients with extracranial metastasis had a poor median survival (3.2 months).\(^10,11,14,15\)

Nieder et al asserted that the most important prognostic factor was KPS.\(^10\) Their study showed a poor survival (2 months) for patients with KPS <70 years. In this study, all patients had BM initially and their survival was 3.28 months with KPS <70 years. Both data Sampson and Nieder had the same from database.\(^10,11\)

The number of brain lesions from melanoma is a factor prognostic used in the scores of assessment of melanoma, like melanoma-specific graded prognostic assessment (GPA), and this article confirms that patients with two to three or more than three BMs had a poor prognosis with 3.4 months.\(^10,16–18\)

In the study of Wronske and Arbit, the 1-year mortality of patients who underwent craniotomy was 60%, whereas our results show higher mortality (70.6%) for the overall group, without discrimination of other variables.\(^4\)

The survival of supratentorial and infratentorial was 14.3 and 15 months, respectively; however, as other studies show, the location of cerebral metastasis was not significant in survival.

The primary goal of surgery is gross-total resection of the tumor with minimal disruption of, or injury to, the brain. In some cases, the additional goal of debulking and relief of mass effect are considered. Account of the criterion of the extent of resection during surgery is a subjective evaluation of the surgeon, and our team has four members, because this is not statistically significant if resection is macroscopically complete or subtotal and de survival (\(p = 0.08\)). Although the mortality of patients who underwent biopsy only was 3.3 months, per Zacest et al showed that a macroscopically complete excision significantly affected survival on univariate analysis (\(p < 0.05\)). Thus, the improvement in the technology and techniques of resection should be craved in our institution.\(^2,5,19\)

Combining the modalities of surgery, WBRT, and chemotherapy has improved in a statistically significant survival (21.5 months) for patients who underwent these three therapies (\(p = 0.02\)).\(^13,20–24\)

Conclusion

The early diagnosis, with total resection of melanoma metastasis and association of adjuvant therapies, showed a positive influence on survival. However, the number of lesions and extracranial disease decreased the survival rates. We believe that further studies will follow protocols to establish treatment.

References


Arquivos Brasileiros de Neurocirurgia Vol. 34 No. 2/2015